Senior woman header
Senior woman header
Photo header of senior man
Photo header of senior man

DIAGNOSTIC INSIGHTS FOR LIFE

CND has launched the Syn-One Test™ to offer physicians and patients an accurate, evidence-based tool to help confirm a diagnosis of a synucleinopathy. And our mission has just begun.

Learn More
Senior woman header
Senior woman header
Senior man header
Photo header of senior man

DIAGNOSTIC INSIGHTS FOR LIFE

CND has launched the Syn-One Test™ to offer physicians and patients an accurate, evidence-based tool to help confirm a diagnosis of a synucleinopathy. And our mission has just begun.
Learn More

Introducing the Syn-One Test™ from CND Life Sciences

Offering physicians and patients an accurate, evidence-based tool to help confirm a diagnosis of a synucleinopathy.

seal icon

CLIA-Certified Pathology Lab

test tube icon

Dedication to Science & Research

DNA icon

Patient-Focused Mission

microscope icon

Quality & Reliability at Our Core

Clarity and Confidence of Syn-One

Having objective, visual proof of a disease process can be invaluable for physicians and patients. That’s why CND Life Sciences developed the Syn-One Test as a way to actually see the presence of abnormal alpha-synuclein in the skin–an important marker for Parkinson’s disease and other disorders known as synucleinopathies.  

Learn More

Our Commitment to Patients

We did not invent the saying “knowledge is power,” but we subscribe to this philosophy as part of our mission. Patients and caregivers rely on physicians to make vital clinical judgments every day, and we are committed to providing reliable diagnostic technologies and useful insights that help optimize care.

Learn more about what drives us.

Learn More

Read our perspectives on the industry, the field of neurodiagnostics, patient care, and other topics.

Insights
January 11, 2022

Solving an Unmet Need: A New Diagnostic Paradigm for Neurodegenerative Disorders

Arriving at a definitive diagnosis of any given neurodegenerative condition is not always easy. Recent…
Insights
December 14, 2021

CND Life Sciences Supports Clinicians With Launch of Biopsy Training Program

A core value at CND Life Sciences is being clinician-minded. We are founded by practicing…
Insights
December 7, 2021

When a Single Diagnosis Doesn’t Tell the Whole Story: Utility of Syn-One Test™ in Patients With Dual Neurologic Diseases

In CND Life Sciences’ newest case study, Dr. Todd Levine describes the case of a…
VIEW ALL INSIGHTS

Check out press releases, news alerts and coverage of CND happenings.

In the News
January 19, 2022

First Patient With Parkinson’s Receives Alpha-Synuclein Vaccine in Phase 1 Study

Vaxxinity, a “purpose-driven biotechnology company committed to democratizing healthcare across the globe,” announced that it…
In the News
December 28, 2021

AC Immune Awarded Two Grants for Research of Potentially Disease-Modifying Parkinson’s Treatments

The Michael J. Fox Foundation for Parkinson’s Research (MJFF) has awarded two grants to AC…
In the News
December 1, 2021

Tyrosine Kinase Inhibitor Shows Potential as Disease-Modifying Treatment for Parkinson’s

Boston- and Atlanta-based clinical-stage pharmaceutical company Inhibikase Therapeutics, Inc. published the biochemical rationale for potentially…
VIEW ALL NEWS
CND CASE STUDIES

For Clinicians: Request a Syn-One Test™ Kit

The Syn-One Test provides objective pathological evidence to aid in the diagnosis of a synucleinopathy. Simply collect three small punch skin biopsies from your patient, send them to our CLIA-certified lab, and CND Life Sciences will provide important visual insights to support a diagnosis. If you are a clinician, click below to order a Syn-One Test Biopsy Kit.

Order a Kit